Prevalence of antinuclear autoantibodies in the serum of normal blood dornors

OBJECTIVE:To examine the presence of serum antinuclear autoantibodies in a healthy population. METHODS: Serum of 500 normal blood donors between 18 and 60 years of age were tested for the presence of autoantibodies. Antinuclear antibodies were detected by indirect immunofluorescence technique using HEp-2 epithelial cells as the substrate. The presence of dnaN was detected by indirect immunofluorescence technique using Critidia lucillae as the substrate. Anti-SSA (RO), anti-SSB (LA), anti-Sm, and anti-RNP were determined by double radial immunodiffusion. RESULTS: In the evaluation of the presence of serum antibodies, antinuclear antibodies were detected in 22.6% of the sera. The presence of other antibodies was not significant. The majority of the titers were 1:40. CONCLUSION: The presence of autoantibodies is not necessarily pathologic and has to be related to the age group, gender, and clinical condition of the patient.

Biodisponibilidade dos Carotenóides do Buriti (Mauritia flexuosa l.) em Ratos

Considerando a magnitude da hipovitaminose A como problema de saúde pública no mundo e a disponibilidade de frutos ricos em pró-vitamina A na região Amazônica, determinou-se a biodisponibilidade dos carotenóides do Buriti (Mauritia flexuosa L.) em ratos. Quarenta e oito ratos machos da linhagem Wistar (Rattus novergicus, var. albinus, Rodentia: Mammalia) recém-desmamados, com peso médio inicial de 33,8 ± 1,7g, foram distribuídos em cinco grupos, ou seja, Grupos: Deficiente, Controle 1200, Controle 2400, Buriti 1200 e Buriti 2400. As rações foram elaboradas de acordo com a recomendação do Committee on Laboratory Animal Diets (1993). Após o período experimental de 28 dias, todos os animais foram sacrificados para a determinação de vitamina A e caroteno no plasma e no fígado. A menor concentração de vitamina A hepática e plasmática foi observada no Grupo Deficiente. Por sua vez, as reservas hepáticas de vitamina A dos animais dos grupos Buriti 1200 e 2400 foram significativamente superiores quando comparados com os grupos Controle 1200 e 2400, respectivamente. Os resultados desse estudo demonstraram ser o buriti uma fonte de pró-vitamina A altamente biodisponível, com eficiência relativa de 254,6% (1200ER/Kg ração) e 179,4% (2400 ER/Kg ração) quando comparado com os respectivos grupos controle, indicando a maior biodisponibilidade dos carotenóides em doses próximas à recomendada.

Interacción trofoblasto - Trypanosoma cruzi: Rol de la fosfatasa alcalina placentaria en la nfección de la placenta humana

La invasión del Trypanosoma cruzi a la célula huésped es un proceso de endocitosis tipo ligando-receptor que produce aumento de Ca2+ citosólico y reorganización de actina cortical. En trabajos anteriores se había observado que la fosfatasa alcalina placentaria (FAP) estaba modificada en las placentas de embarazadas chagásicas con respecto a las placentas control. El T.cruzi secreta fosfolipasa C, y ésta podría tener alguna función importante en la interiorización del parásito a la célula huésped. La FAP es una enzima unida a membrana por glicosilfosfatidilinositol, y esta molécula es susceptible a la acción de la fosfolipasa C, por lo que se propone que la FAP podría estar involucrada en el proceso de interiorización del parásito a la célula placentaria, actuando como gatilladora de señales. Objetivo General: Determinar si la FAP y componentes del citoesqueleto del sinciciotrofoblasto de placentas humanas están involucrados en la interiorización del T. cruzi en infecciones realizadas in vitro. Objetivos específicos: - Analizar la interacción de la FAP de sinciciotrofoblasto de placentas humanas con el T. cruzi en el proceso de interiorización a células placentarias en un modelo de infección in vitro y estudiar la capacidad de invasividad del parásito a la célula placentaria bajo ciertas condiciones experimentales que alteran el funcionamiento normal de la FAP. - Determinar la existencia de reorganización del citoesqueleto de las células placentarias en la infección in vitro con T. cruzi. - Comparar los resultados obtenidos con la placenta con experiencias similares realizadas en células HEP/2. Metodología: Mediante la utilización de un sistema in vitro que simule infección placentaria por el T. cruzi, se determinó la participación de la FAP en este proceso. Los estudios se realizaron entre vellosidades placentarias humanas y tripomastigotes del T. cruzi y entre células HEp2 y tripomastigotes del T. cruzi.

Avaliacao da Relacao entre a Doenca Hepatica Nao Gordurosa e CAD utilizando TCMF

Fundamento: Alguns fatores de risco para a aterosclerose são acompanhados pela doença hepática gordurosa não alcoólica (DHGNA). Desejamos usar a tomografia computadorizada multi-fatias (TCMF) como a técnica para encontrar relação entre a DHGNA e a doença arterial coronariana (DAC). Objetivo: A relação entre a DHGNA e a DAC foi investigada através de TCMF. Métodos: Um total de 372 indivíduos com ou sem sintomas cardíacos, que foram submetidos à angiografia por TCMF, foram incluídos no estudo. Os pacientes foram divididos em dois grupos, de acordo com a presença da DHGNA. Os segmentos arteriais coronarianos foram avaliados visualmente via angiografia por TCMF. Com base no grau de estenose arterial coronariana, aqueles com placas ausentes ou mínimas foram considerados como normais, enquanto aqueles que apresentavam estenose de menos do que 50% e no mínimo uma placa foram considerados como portadores da doença arterial coronariana não obstrutiva (não-obsDAC). Os pacientes que apresentaram no mínimo uma placa e estenose arterial coronariana de 50% ou mais foram considerados como portadores de doença arterial coronariana obstrutiva (obsDAC). A DHGNA foi determinada de acordo com o protocolo de TCMF, utilizando a densidade hepática. Resultados: De acordo com a densidade hepática, o número de pacientes com doença hepática gordurosa não alcoólica (grupo 1) foi de 204 (149 homens, 54,8%) e com fígado normal (grupos 2) foi de 168 (95 homens, 45.2%). Houve 50 (24,5%) não-obsDAC e 57 (27,9%) casos de obsDAC no Grupo 1, e 39 (23,2%) não-obsDAC e 23 (13,7%) casos de obsDAC no Grupo 2. Conclusões: O presente estudo utilizando TCMF demonstrou que a frequência da doença arterial coronariana em pacientes com NAFDL foi significativamente superior do que nos pacientes em NAFDL.

Endocytosis-inducer adhesins produced by enteropathogenic serogroups of Escherichia coli participate on bacterial attachment to infant enterocytes

Enteropathogenic E. coli (EPEC) infection of Hep-2 cells preoceeds through bacterial attachment to cell surface and internalization of adhered bacteria. EPEC attachment is a prerequisite for cell infection and is mediated by adhesins that recognize carbohydrate-containing receptors on cell membrane. Such endocytosis-inducer adhesins (EIA) also promote EPEC binding to infant enterocytes, suggesting that EIA may have an important role on EPEC gastroenteritis.

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study.

Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. The aim of the present phase II study was to examine virologic response rates with vaniprevir in combination with pegylated interferon alpha-2a (Peg-IFN-α-2a) plus ribavirin (RBV). In this double-blind, placebo-controlled, dose-ranging study, treatment-naïve patients with HCV genotype 1 infection (n = 94) were randomized to receive open-label Peg-IFN-α-2a (180 μg/week) and RBV (1,000-1,200 mg/day) in combination with blinded placebo or vaniprevir (300 mg twice-daily [BID], 600 mg BID, 600 mg once-daily [QD], or 800 mg QD) for 28 days, then open-label Peg-IFN-α-2a and RBV for an additional 44 weeks. The primary efficacy endpoint was rapid viral response (RVR), defined as undetectable plasma HCV RNA at week 4. Across all doses, vaniprevir was associated with a rapid two-phase decline in viral load, with HCV RNA levels approximately 3 log(10) IU/mL lower in vaniprevir-treated patients, compared to placebo recipients. Rates of RVR were significantly higher in each of the vaniprevir dose groups, compared to the control regimen (68.8%-83.3% versus 5.6%; P < 0.001 for all comparisons). There were numerically higher, but not statistically significant, early and sustained virologic response rates with vaniprevir, as compared to placebo. Resistance profile was predictable, with variants at R155 and D168 detected in a small number of patients. No relationship between interleukin-28B genotype and treatment outcomes was demonstrated in this study. The incidence of adverse events was generally comparable between vaniprevir and placebo recipients; however, vomiting appeared to be more common at higher vaniprevir doses. CONCLUSION: Vaniprevir is a potent HCV protease inhibitor with a predictable resistance profile and favorable safety profile that is suitable for QD or BID administration.

Atividades citotóxica e hemolítica em Escherichia coli uropatogênicas

Estudamos 59 Escherichia coli uropatogênicas (ECUP) obtidas de pacientes com infecção urinária e 30 E. coli originárias das fezes de indivíduos normais. Cada amostra originou-se de um paciente ou controle. Verificamos que 44% e 3,3% respectivamente eram hemolíticas em meio sólido segundo a origem. Apenas 15% das ECUP hemolíticas produziram alfa-hemolisina, isoladamente ou em associação com ß-hemolisina. A alfa-hemolisina correspondeu a 92% das amostras com atividade hemolítica. Não encontramos correlação entre títulos de alfa-hemolisina e o sítio de origem das ECUP (infecção alta ou baixa). Em 71% das ECUP e 30% das E. coli fecais detectamos a produção de citotoxina com ação citocida para linhagens celulares epitelióides como Vero, He-La e Hep-2 e pouco ativa para fibroblastos de embrião de galinha. A produção desta citotoxina não apresenta correlação com a síntese de hemolisinas. Não verificamos associação entre títulos citotóxicos e origem das ECUP. Certas características biológicas desta citotoxina como a resposta morfológica que determina nas células, o aumento dos títulos citotóxicos com o tempo, sua atividade citocida irreversível e sua termolabilidade sugerem analogia com a Verotoxina (VT) de E. coli. As células afetadas pela citoxina inicialmente mostram aspecto estrelado, tornam-se arredondadas e finalmente desprendem-se do seu suporte. É sugerido que a produção de citotoxina por E. coli aderidas às mucosas do trato urinário possa contribuir para a agressão ao uroepitélio.

Evidence against a direct role of klotho in insulin resistance.

The klotho gene may be involved in the aging process. Klotho is a coactivator of FGF23, a regulator of phosphate and vitamin D metabolism. It has also been reported to be downregulated in insulin resistance syndromes and paradoxically to directly inhibit IGF-1 and insulin signaling. Our aim was to study klotho's regulation and effects on insulin and IGF-1 signaling to unravel this paradox. We studied klotho tissue distribution and expression by quantitative real-time polymerase chain reaction and Western blotting in obese Zucker rats and high-fat fed Wistar rats, two models of insulin resistance. Klotho was expressed in kidneys but at much lower levels (<1.5%) in liver, muscle, brain, and adipose tissue. There were no significant differences between insulin resistant and control animals. We next produced human recombinant soluble klotho protein (KLEC) and studied its effects on insulin and IGF-1 signaling in cultured cells. In HEK293 cells, FGF23 signaling (judged by FRS2-alpha and ERK1/2 phosphorylation) was activated by conditioned media from KLEC-producing cells (CM-KLEC); however, IGF-1 signaling was unaffected. CM-KLEC did not inhibit IGF-1 and insulin signaling in L6 and Hep G2 cells, as judged by Akt and ERK1/2 phosphorylation. We conclude that decreased klotho expression is not a general feature of rodent models of insulin resistance. Further, the soluble klotho protein does not inhibit IGF-1 and/or insulin signaling in HEK293, L6, and HepG2 cells, arguing against a direct role of klotho in insulin signaling. However, the hypothesis that klotho indirectly regulates insulin sensitivity via FGF23 activation remains to be investigated.

Antitumor and Antiviral Activity of Colombian Medicinal Plant Extracts

Extracts of nine species of plants traditionally used in Colombia for the treatment of a variety of diseases were tested in vitro for their potential antitumor (cytotoxicity) and antiherpetic activity. MTT (Tetrazolium blue) and Neutral Red colorimetric assays were used to evaluate the reduction of viability of cell cultures in presence and absence of the extracts. MTT was also used to evaluate the effects of the extracts on the lytic activity of herpes simplex virus type 2 (HSV-2). The 50% cytotoxic concentration (CC50) and the 50% inhibitory concentration of the viral effect (EC50) for each extract were calculated by linear regression analysis. Extracts from Annona muricata, A. cherimolia and Rollinia membranacea, known for their cytotoxicity were used as positive controls. Likewise, acyclovir and heparin were used as positive controls of antiherpetic activity. Methanolic extract from Annona sp. on HEp-2 cells presented a CC50 value at 72 hr of 49.6x103mg/ml. Neither of the other extracts examined showed a significant cytotoxicity. The aqueous extract from Beta vulgaris, the ethanol extract from Callisia grasilis and the methanol extract Annona sp. showed some antiherpetic activity with acceptable therapeutic indexes (the ratio of CC50 to EC50). These species are good candidates for further activity-monitored fractionation to identify active principles.

Cytotoxic and Antiviral Activities of Colombian Medicinal Plant Extracts of the Euphorbia genus

Forty-seven plant extracts of 10 species of the genus Euphorbia (Euphorbiaceae) used by Colombian traditional healers for the treatment of ulcers, cancers, tumors, warts, and other diseases, were tested in vitro for their potential antitumour (antiproliferative and cytotoxic) and antiherpetic activity. To evaluate the capacity of the extracts to inhibit the lytic activity of herpes simplex virus type 2 (HSV-2) and the reduction of viability of infected or uninfected cell cultures, the end-point titration technique (EPTT) and the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] colorimetric assay were used, respectively. The therapeutic index of the positive extracts for the antiviral activity was determined by calculating the ratio CC50 (50% cytotoxic concentration) over IC50 (50% inhibitory concentration of the viral effect). Five of the 47 extracts (11%) representing 3 out of 10 Euphorbia species (30%) exhibited antiherpetic action; the highest activity was found in the leaf/stem water-methanol extracts from E. cotinifolia and E. tirucalli. The therapeutic indexes of these two plant species were > 7.1; these extracts exhibited no cytotoxicity. Six extracts (13%) representing 4 plant species (40%) showed cytotoxic activity. The highest cytotoxicity was found in the dichloromethane extract obtained from E. cotinifolia leaves and the CC50 values for the most susceptible cell lines, HEp-2 and CHO, were 35.1 and 18.1 µg/ml, respectively.

Cytotoxicity and potential antiviral evaluation of violacein produced by Chromobacterium violaceum

Natural products are an inexhaustible source of compounds with promising pharmacological activities including antiviral action. Violacein, the major pigment produced by Chromobacterium violaceum, has been shown to have antibiotic, antitumoral and anti-Trypanosoma cruzi activities. The goal of the present work was to evaluate the cytotoxicity of violacein and also its potential antiviral properties.The cytotoxicity of violacein was investigated by three methods: cell morphology evaluation by inverted light microscopy and cell viability tests using the Trypan blue dye exclusion method and the MTT assay. The cytotoxic concentration values which cause destruction in 50% of the monolayer cells (CC50) were different depending on the sensitivity of the method. CC50 values were > 2.07 ± 0.08 µM for FRhK-4 cells: > 2.23 ± 0.11 µM for Vero cells; > 2.54 ± 0.18 µM for MA104 cells; and > 2.70 ± 0.20 µM for HEp-2 cells. Violacein showed no cytopathic inhibition of the following viruses: herpes simplex virus type 1 (HSV-1) strain 29-R/acyclovir resistant, hepatitis A virus (strains HM175 and HAF-203) and adenovirus type 5 nor did it show any antiviral activity in the MTT assay. However violacein did show a weak inhibition of viral replication: 1.42 ± 0.68%, 14.48 ± 5.06% and 21.47 ± 3.74% for HSV-1 (strain KOS); 5.96 ± 2.51%, 8.75 ± 3.08% and 17.75 ± 5.19% for HSV-1 (strain ATCC/VR-733); 5.13 ± 2.38 %, 8.18 ± 1.11% and 8.51 ± 1.94% for poliovirus type 2; 8.30 ± 4.24%; 13.33 ± 4.66% and 24.27 ± 2.18% for simian rotavirus SA11, at 0.312, 0.625 and 1.250 mM, respectively, when measured by the MTT assay.

Isolation of respiratory syncytial virus from nasopharyngeal aspirates stored at 20ºC from one to fifteen months after collection

Cell culture isolation is used for recovering respiratory syncytial virus (RSV) from respiratory specimens. As RSV is a thermolabile virus, specimens destined for inoculation into cell culture require special transport, handling, and storage. The isolation rate of RSV from nasopharyngeal aspirates (NPA) stored at 20ºC for one to 15 months after collection was investigated. A total of 126 samples considered positive for RSV by indirect fluorescence-antibody were tested by virus isolation in HEp-2 cell culture. RSV was isolated from 47/126 specimens (37.3%). These results show that RSV may be recovered from NPA stored at 20ºC by cell culture.